Haghighi Seyedeh Kimia Javadi, Fardid Reza, Safari Arash
Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Ionizing and Non-Ionizing Radiation Protection Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Curr Drug Res Rev. 2025;17(2):132-141. doi: 10.2174/0125899775300432240625045414.
Radiation therapy is the most common modality to treat various types of cancers. The use of radiosensitizers as an adjuvant therapy to increase the sensitivity of tumors against radiation and to improve the efficiency of radiotherapy has risen over the past years. Metformin, the first-line drug in type two diabetes has attracted the researcher's attention because of its anti-cancer and anti-proliferative properties and many studies have been conducted to investigate the radiosensitization effects of metformin in different types of malignancies.
This review aims to gather the existing evidence of radiosensitizing effects of metformin in animal and clinical studies.
Various databases like PubMed, Scopus, and Google Scholar were searched over a period of 35 years for this review.
The results include 54 studies on the radiosensitization effect of metformin in and clinical conditions including breast, colorectal, prostate, lung, liver, and other cancers.
This review shows that metformin in animal and clinical studies appears to be a potential radiosensitizer for many types of cancers. However, further investigations are needed to determine whether metformin can be used as a radiosensitizer in adjuvant radiotherapy.
放射治疗是治疗各类癌症最常用的方式。在过去几年中，使用放射增敏剂作为辅助治疗以提高肿瘤对辐射的敏感性并改善放射治疗效果的情况有所增加。二甲双胍作为2型糖尿病的一线药物，因其抗癌和抗增殖特性而引起了研究人员的关注，并且已经开展了许多研究来探究二甲双胍在不同类型恶性肿瘤中的放射增敏作用。
本综述旨在收集二甲双胍在动物和临床研究中放射增敏作用的现有证据。
为进行本综述，在35年的时间里检索了诸如PubMed、Scopus和谷歌学术等各种数据库。
结果包括54项关于二甲双胍在乳腺癌、结直肠癌、前列腺癌、肺癌、肝癌和其他癌症等动物和临床条件下放射增敏作用的研究。
本综述表明，在动物和临床研究中，二甲双胍似乎是多种癌症的潜在放射增敏剂。然而，需要进一步研究以确定二甲双胍是否可作为辅助放射治疗中的放射增敏剂。
